নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - triamcinolone acetonide 0.055%{relative};   - nasal spray suspension - 55 mcg/dose - active: triamcinolone acetonide 0.055%{relative}   excipient: benzalkonium chloride disodium edetate dihydrate dispersible cellulose glucose hydrochloric acid polysorbate 80 purified water sodium hydroxide - telnase is indicated for the treatment and prophylaxis of seasonal and perennial allergic rhinitis in adults and children over 6 years of age.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - ketoprofen 100mg - modified release capsule - 100 mg - active: ketoprofen 100mg excipient: colloidal silicon dioxide erythrosine ethylcellulose gelatin non pariel beads, maize starch + sucrose opacode white s-1-7020 patent blue v purified talc shellac sodium laurilsulfate titanium dioxide

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - clopidogrel bisulfate, form ii 97.875mg equivalent to 75 mg free base - film coated tablet - 75 mg - active: clopidogrel bisulfate, form ii 97.875mg equivalent to 75 mg free base excipient: carnauba wax hydrogenated castor oil hyprolose macrogol 6000 mannitol microcrystalline cellulose opadry pink 32k14834 - prevention of vascular ischaemia associated with secondary atherothrombotic events (mi, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome plavix is indicated in combination with aspirin for patients with: · unstable angina or non-st elevation mi. plavix is indicated for early and long-term reduction of atherothrombotic events (myocardial infarction, stroke, vascular death and refractory ischaemia) whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). · st-segment elevation acute myocardial infarction. in this population, plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - rifampicin 450mg - tablet - 450 mg - active: rifampicin 450mg

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - rifampicin 600mg - tablet - 600 mg - active: rifampicin 600mg excipient: acacia calcium stearate carmellose sodium carnauba wax colloidal silicon dioxide colophony erythrosine ethanol gelatin hard paraffin kaolin lactose monohydrate magnesium carbonate magnesium stearate maize starch microcrystalline cellulose povidone purified talc purified water sodium laurilsulfate sucrose titanium dioxide white beeswax - tuberculosis rifampicin is indicated in the treatment of all forms of tuberculosis, including fresh, advanced, chronic and drug resistant cases. rifampicin should be used in conjunction with at least one other antituberculosis medicine. leprosy rifampicin is indicated in the treatment of multibacillary and paucibacillary leprosy to effect a conversion of the infectious state to a non-infectious state. rifampicin should be used in conjunction with at least one other anti-leprosy drug. methicillin-resistant staphylococcal infections (mrsa) rifampicin can be used as an alternative to vancomycin in the treatment of mrsa. in such circumstances an appropriate companion antibiotic (e.g. fusidic acid) should always be employed. serious staphylococcal infections rifampicin has been used for the treatment of both life-threatening and serious staphylococcal infections. in such circumstances an appropriate companion antibiotic should be employed. brucellosis rifampicin may be used for the treatment of brucellosis. in such circumstances doxycycline should also be used. meningococcal carriers rifampicin is indicated for the treatment of asymptomatic carriers of n. meningitidis to eliminate meningococci from the nasopharynx. (rifampicin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms). haemophilus influenzae rifampicin is indicated for the treatment of asymptomatic carriers of h influenzae and as chemoprophylaxis of exposed children of 4 years of age or younger. other infections infections caused by rifampicin-sensitive microorganisms such as staphylococci, streptococci, n gonorrhoeae, proteus sp., h. influenzae, e. coli and legionella sp. to prevent emergence of resistant organisms, rifampicin should be given with another antibacterial agent to which the organism has been shown to be susceptible.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - disopyramide 150mg (as base) - capsule - 150 mg - active: disopyramide 150mg (as base) excipient: gelatin magnesium stearate maize starch purified talc starch titanium dioxide

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - tiaprofenic acid 200mg - tablet - 200 mg - active: tiaprofenic acid 200mg

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - tiaprofenic acid 300mg - tablet - 300 mg - active: tiaprofenic acid 300mg

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - alimemazine tartrate 0.6%{relative};  ; alimemazine tartrate 0.6%{relative} - syrup - 30 mg/5ml - active: alimemazine tartrate 0.6%{relative}   excipient: ascorbic acid citric acid as monohydrate ethanol prunus armeniaca purified water sodium benzoate sodium citrate dihydrate sodium metabisulfite sodium sulfite sucrose active: alimemazine tartrate 0.6%{relative} excipient: ascorbic acid citric acid monohydrate ethanol prunus armeniaca purified water sodium benzoate sodium citrate dihydrate sodium metabisulfite sodium sulfite sucrose - · urticaria

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]);  ; influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]);  ; influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]);   - solution for injection - 10µg/15µg/15µg per dose - active: influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)])   influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)])   influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)])   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin sodium chloride water for injection